Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology argues that the take-home message for the follow-up on the RESONATE trial is the role of ibrutinib for all types of CLL patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
Advertisement